Benzoyl Peroxide Plus Clindamycin vs Azelaic Acid — What a Head-to-Head Trial Shows in Acne Vulgaris

Acne vulgaris is a chronic inflammatory disease of the hair follicles and sebaceous glands, affecting most teenagers at some point in life, and in a significant proportion of adults — especially women — persisting or recurring well past adolescence. It rests on four interconnected mechanisms: excess sebum production, abnormal keratinization of the follicular opening, proliferation of Cutibacterium acnes bacteria, and inflammation, which ultimately produces the visible pustules, papules, and redness.

For mild-to-moderate acne vulgaris, topical therapies remain first-line treatment, and two substances appear most often among them: benzoyl peroxide (alone or combined with a topical antibiotic, most commonly clindamycin) and azelaic acid. Benzoyl peroxide works primarily through antibacterial and exfoliating action, and adding clindamycin strengthens the antibacterial and anti-inflammatory effect. Azelaic acid, a naturally occurring dicarboxylic acid, has weaker but multidirectional effects — antibacterial, anti-inflammatory, and reducing post-inflammatory hyperpigmentation — and is often promoted as the option perceived as "gentler on the skin."

The problem is that the efficacy and tolerability of both approaches have rarely been compared directly in a single clinical trial — most data come from separate trials of each substance versus placebo, which makes a fair comparison difficult. That is why a head-to-head trial, testing both therapies simultaneously in comparable groups of patients, has particular practical value: it lets us answer which option to choose, not just whether a given option works better than nothing.

In 2016, the Journal of the European Academy of Dermatology and Venereology (JEADV) published a multicentre, randomized clinical trial designed specifically to directly compare the efficacy and tolerability of a benzoyl peroxide 3%/clindamycin 1% gel with an azelaic acid 20% gel in treating mild-to-moderate acne vulgaris.

It's worth noting that this was a single-blind, not double-blind, trial — meaning the physician evaluating skin severity did not know which preparation a given patient was receiving, but the patient themselves could potentially tell the two gels apart by consistency or smell. This is a weaker methodological standard than full double-blinding, which is worth keeping in mind when interpreting the results, especially those based on patients' own subjective assessment of tolerability.

The most practically relevant finding from this trial concerns speed of action. The advantage of benzoyl peroxide with clindamycin was clear and statistically significant already at the first evaluated time point — after 4 weeks of therapy — not only toward the end of the trial. For a patient, this means that choosing the more effective therapy from the start can shorten the period during which acne remains visible and affects self-esteem, which has real clinical significance, not just statistical significance.

The difference persisted and widened through the end of the 12-week observation period — both for purely inflammatory lesions (papules, pustules) and for the total count of all acne lesions, including comedones. This suggests that the advantage of benzoyl peroxide with clindamycin in this trial was not a transient early effect but was sustained throughout the treatment period.

Intuitively, one might assume that benzoyl peroxide — a substance known for its potential to dry out and irritate the skin, especially early in treatment — would be less well tolerated than azelaic acid, often positioned in advertising as the gentler option. The results of this trial show the opposite.

In absolute numbers, application-site reactions were recorded in 17 patients (24 events in total) in the benzoyl peroxide/clindamycin group versus 39 patients (60 events in total) in the azelaic acid group. The trial's authors summarized tolerability of both therapies as acceptable, and rated the safety profile of benzoyl peroxide with clindamycin as favorable — which, combined with the higher efficacy, led to the conclusion that this combination was superior in the studied population.

Direct comparisons of two active therapies are rarer in dermatology than testing each one separately against placebo, which is why this trial has particular practical value — it shows not just that both substances work, but which one, in this specific, well-designed trial, worked faster and with fewer skin irritations. It's worth remembering, though, that this is a single trial of moderate evidentiary strength, conducted in a specific, limited population of patients with mild-to-moderate acne.